J&J analgesic
This article was originally published in The Tan Sheet
Executive Summary
McNeil is reportedly preparing for the market launch of a new OTC ibuprofen product to be called Zymaxin. McNeil Consumer received FDA approval for an ANDA covering a 200 mg ibuprofen tablet in March and filed for the Zymaxin trademark in March 1993. J&J announced its re-entry into the ibuprofen pain-reliever market in July with the launch of its Arthritis Foundation line, which includes an ibuprofen-based product ("The Tan Sheet" July 11, p. 8). J&J got out of ibuprofen products in 1992 when it discontinued marketing Medipren